Infensa Bioscience
At Infensa we are committed to bringing the promise of peptide therapy to life for patients suffering a heart attack or stroke

Funnel-web Spider
Infensa is based on a remarkable peptide (Hi1a) from venom of an Australian funnel-web spider that protects brain nerve cells and heart muscle cells from oxygen deprivation

Protects Brain
Hi1a protects the brain from stroke-induced injury even when delivered 8 hours after stroke onset

Protects Heart
Hi1a protects hearts from the injury suffered during a heart attack, and helps preserve donor hearts for transplantation

Game-changing Drugs
Infensa is uniquely placed to develop game-changing drugs for cardiovascular disorders that kill 15 million people a year
Saving hearts and minds
An overview of the opportunity
An overview of the opportunity
- First-in-class drugs with addressable worldwide market of tens of millions of patients per year
- Ability of a single drug class to address multiple diseases enables staged clinical development with continuous value creation: initial focus on heart transplant (low cost) followed by heart attack and stroke (higher cost, massive markets)
- Other potential indications: traumatic head injury, hypoxic brain injury (cerebral palsy) retinal artery thrombosis, kidney artery thrombosis, cardiac and brain surgery, endarterectomy, heart valve replacement
- Key asset protected by patents granted in USA, EU, Japan, and Australia
- Outstanding executive team with more than a century combined experience in biotech sector
What Our Patient Say
Saving hearts and minds
Our Team
Led by Passionate Experts
Ananth Siva
Non Executive Chair (BS, MBA)
- CEO, Movius
- Co-founder Infensa Bioscience
- Previously MD at 247.AI and VP at Trimble Navigation
- Has worked across early to late stage start-ups and a Fortune 100 corporation
Prof. Bob Graham, AO
MBBS, MD, FRACP, FAA
- Co-founder, Infensa Bioscience.
- Executive Director of Victor
- Chang Cardiac Research Institute for 26 years.
- 40 years experience in clinical cardiovascular research.
Dr Jane Andrews
PhD, GradDipAppFin
- CEO, Magic Pudding
- Non-Executive Director, TechnologyOne;
- Member, Brisbane Angels.
- 15 years experience in biotech sector;
- 3 years VC experience.
Glenn Kerhof
BCom, MBA
- Chair, George Clinical.
- Previously CEO, Chiltern Int. and VP Global Operations, Charles River Labs.
- 20 years experience in pharmaceutical services sector.